A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease

Marieke E.B. Welzen; Roger J.M. Brüggemann; J. Merlijn Van Den Berg; Heleen W. Voogt; Jos H. Gilissen; Dasja Pajkrt; Nigel Klein; David M. Burger; Adilia Warris

doi:10.1097/INF.0b013e3182195808

A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease

Marieke E.B. Welzen
, Roger J.M. Brüggemann
, J. Merlijn Van Den Berg
, Heleen W. Voogt
, Jos H. Gilissen
, Dasja Pajkrt
, Nigel Klein
, David M. Burger
, Adilia Warris

Research output: Contribution to journal › Article › peer-review

51 Citations (Scopus)

Abstract

Posaconazole (PSZ) may be an attractive alternative for antifungal prophylaxis in children with chronic granulomatous disease. Experience with PSZ in pediatric patients is limited, and no specific dose recommendations exist. A twice daily dosing algorithm based on allometric scaling (body-weight based) for PSZ results in adequate exposure and appears to be safe in children with chronic granulomatous disease.

Original language	English
Pages (from-to)	794-797
Number of pages	4
Journal	Pediatric Infectious Disease Journal
Volume	30
Issue number	9
DOIs	https://doi.org/10.1097/INF.0b013e3182195808
Publication status	Published - Sept 2011
Externally published	Yes

Keywords

CGD
children
pharmacokinetics
posaconazole
prophylaxis

Access to Document

10.1097/INF.0b013e3182195808

Cite this

@article{9e8f4466150946408c6646ac396c5fa4,

title = "A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease",

abstract = "Posaconazole (PSZ) may be an attractive alternative for antifungal prophylaxis in children with chronic granulomatous disease. Experience with PSZ in pediatric patients is limited, and no specific dose recommendations exist. A twice daily dosing algorithm based on allometric scaling (body-weight based) for PSZ results in adequate exposure and appears to be safe in children with chronic granulomatous disease.",

keywords = "CGD, children, pharmacokinetics, posaconazole, prophylaxis",

author = "Welzen, \{Marieke E.B.\} and Br{\"u}ggemann, \{Roger J.M.\} and \{Van Den Berg\}, \{J. Merlijn\} and Voogt, \{Heleen W.\} and Gilissen, \{Jos H.\} and Dasja Pajkrt and Nigel Klein and Burger, \{David M.\} and Adilia Warris",

note = "Funding Information: R.B. has received honoraria for consultancy, speaker's fees, and educational or clinical research grants from Schering-Plough and Pfizer. He has received speaker's fees from Gilead. A.W. has received honoraria for consultancy from Pfizer, Schering-Plough, and Gilead, and educational grants from Pfizer and Gilead. N.K. was supported in part by TEDDY (Task-force in Europe for Drug Development for the Young). All other authors have no conflicts. ",

year = "2011",

month = sep,

doi = "10.1097/INF.0b013e3182195808",

language = "English",

volume = "30",

pages = "794--797",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease

AU - Welzen, Marieke E.B.

AU - Brüggemann, Roger J.M.

AU - Van Den Berg, J. Merlijn

AU - Voogt, Heleen W.

AU - Gilissen, Jos H.

AU - Pajkrt, Dasja

AU - Klein, Nigel

AU - Burger, David M.

AU - Warris, Adilia

N1 - Funding Information: R.B. has received honoraria for consultancy, speaker's fees, and educational or clinical research grants from Schering-Plough and Pfizer. He has received speaker's fees from Gilead. A.W. has received honoraria for consultancy from Pfizer, Schering-Plough, and Gilead, and educational grants from Pfizer and Gilead. N.K. was supported in part by TEDDY (Task-force in Europe for Drug Development for the Young). All other authors have no conflicts.

PY - 2011/9

Y1 - 2011/9

N2 - Posaconazole (PSZ) may be an attractive alternative for antifungal prophylaxis in children with chronic granulomatous disease. Experience with PSZ in pediatric patients is limited, and no specific dose recommendations exist. A twice daily dosing algorithm based on allometric scaling (body-weight based) for PSZ results in adequate exposure and appears to be safe in children with chronic granulomatous disease.

AB - Posaconazole (PSZ) may be an attractive alternative for antifungal prophylaxis in children with chronic granulomatous disease. Experience with PSZ in pediatric patients is limited, and no specific dose recommendations exist. A twice daily dosing algorithm based on allometric scaling (body-weight based) for PSZ results in adequate exposure and appears to be safe in children with chronic granulomatous disease.

KW - CGD

KW - children

KW - pharmacokinetics

KW - posaconazole

KW - prophylaxis

UR - https://www.scopus.com/pages/publications/80051923473

U2 - 10.1097/INF.0b013e3182195808

DO - 10.1097/INF.0b013e3182195808

M3 - Article

AN - SCOPUS:80051923473

SN - 0891-3668

VL - 30

SP - 794

EP - 797

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 9

ER -

A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this